Biorelevant dissolution methods and their applications in in vitroin vivo correlations for oral formulations

Open Drug Delivery Journal

Volumn 4, Issue SPEC. ISSUE 1, 2010, Pages 2-13

  Fotaki, Nikoletta ^a   Vertzoni, Maria ^b  

^a University of Bath   (United Kingdom)

^b UNIVERSITY OF ATHENS   (Greece)

Author keywords

Biorelevant media; Colon; Dissolution; Hydrodynamics; Ivivc; Ivivr; Small intestine; Stomach

Indexed keywords

ACETIC ACID; BILE SALT; BUFFER; CELECOXIB; DANAZOL; DIPYRIDAMOLE; DISODIUM HYDROGEN PHOSPHATE; DODECYL SULFATE SODIUM; GLYCEROL OLEATE; HYDROCHLORIC ACID; ISOSORBIDE 5 NITRATE; MALEIC ACID; PEPSIN A; PHOSPHATIDYLCHOLINE; PHOSPHORIC ACID; SODIUM CHLORIDE; SODIUM DIHYDROGEN PHOSPHATE; SODIUM HYDROXIDE; SULPIRIDE; TAUROCHOLIC ACID; TRITON X 100;

ARTICLE; COMPUTER PROGRAM; DIET RESTRICTION; DRUG BIOAVAILABILITY; DRUG DOSAGE FORM; DRUG FORMULATION; DRUG SOLUBILITY; DRUG STABILITY; FOOD DRUG INTERACTION; FOOD INTAKE; GASTROINTESTINAL TRACT; HYDRODYNAMICS; IN VITRO STUDY; IN VIVO STUDY; OSMOLALITY; PH; PREDICTION; PRIORITY JOURNAL; SIMULATION; STOMACH JUICE; SURFACE TENSION;

EID: 77957724075     PISSN: None     EISSN: 18741266     Source Type: Journal    
DOI: 10.2174/1874126601004020002     Document Type: Article

References (69)

1. Lennernäs, H.; Abrahamsson, B. The use of biopharmaceutic classification of drugs in drug discovery and development: current status and future extension. J. Pharm. Pharmacol., 2005, 57, 273-285.
2. Dressman, J.B.; Amidon, G.L.; Reppas, C.; Shah, V.P. Dissolution testing as a prognostic tool for oral drug absorption: Immediate release dosage forms. Pharm. Res., 1998, 15, 11-22.
3. Uppoor, V. R. Regulatory perspectives on in vitro (dissolution)/in vivo (bioavailability) correlations. J. Control. Release, 2001, 72, 127-132.
4. Galia, E.; Nicolaides, E.; Hörter, D.; Löbenberg, R.; Reppas, C.; Dressman, J.B. Evaluation of various dissolution media for predicting in vivo performance of class I and II drugs. Pharm. Res., 1998, 15, 698-705.
5. Dressman, J.B.; Vertzoni, M.; Goumas, K.; Reppas, C. Estimating drug solubility in the gastrointestinal tract. Adv. Drug Deliv. Rev., 2007, 59, 591-602.
6. Jantratid, E.; Janssen, N.; Reppas, C.; Dressman, J.B. Dissolution media simulating conditions in the proximal human gastrointestinal tract: an update. Pharm Res., 2008, 25, 1663-1676.
7. Nicolaides, E.; Symillides, M.; Dressman, J.B.; Reppas, C. Biorelevant dissolution testing to predict the plasma profile of lipophilic drugs after oral administration. Pharm. Res., 2001, 18, 380-388.
8. Dressman, J.B.; Reppas, C. In vitro-in vivo correlations for lipophilic, poorly water-soluble drugs. Eur. J. Pharm. Sci., 2000, 11, S73-S80.
9. Hörter, D.; Dressman, J.B. Influence of physicochemical properties on dissolution of drugs in the gastrointestinal tract. Adv. Drug Deliv. Rev., 2001, 46, 75-87.
10. Vertzoni, M.; Dressman, J.; Butler, J.; Hempenstall, J.; Reppas, C. Simulation of fasting gastric conditions and its importance for the in vivo dissolution of lipophilic compounds. Eur J. Pharm. Biopharm., 2005, 60, 413-417.
11. Diakidou, A.; Vertzoni, M.; Abrahamsson, B.; Dressman, J.; Reppas, C. Simulation of lipolysis and prediction of felodipine release from a matrix tablet in the fed stomach. Eur. J. Pharm. Sci., 2009, 37, 133-140.
12. Abrahamsson, B.; Albery, T.; Eriksson, A.; Gustafsson, I.; Sjöberg, M. Food effects on tablet disintegration. Eur. J. Pharm. Sci., 2004, 22, 165-172.
13. Shono, Y.; Jantratid, E.; Janssen, N.; Kesisoglou, F.; Mao, Y.; Vertzoni, M.; Reppas, C.; Dressman, J.B. Prediction of food effects on the absorption of celecoxib based on biorelevant dissolution testing coupled with physiologically based pharmacokinetic modeling. Eur. J. Pharm. Biopharm., 2009, 73, 107-114.
14. USP, The United States Pharmacopeia (USP 24), United States Pharmacopeial Convention, Inc., Rockville MD, 2000.
15. Galia, E.; Horton, J.; Dressman, J.B. Albendazole generics-A comparative in vitro study. Pharm. Res., 1999, 16, 1871-1875.
16. Vertzoni, M.; Pastelli, E.; Psachoulias, D.; Kalantzi, L.; Reppas, C., Estimation of intragastric solubility of drugs: In what medium? Pharm. Res., 2007, 24, 909-917.
17. Aburub, A.; Risley, D.S.; Mishra, D. A critical evaluation of fasted state simulating gastric fluid (FaSSGF) that contains sodium lauryl sulfate and proposal of a modified recipe. Int. J. Pharm., 2008, 347, 16-22.
18. Chen, L.; Wesley, J.; Bhattachar, S.; Ruiz, B.; Bahash, K.; Babu, S. Dissolution behavior of a poorly water soluble compound in the presence of Tween 80. Pharm. Res., 2003, 20, 797-801.
19. Committee on Codex Specification Food Chemicals Codex, 3rd ed.; National Academy Press: Washington, 1981.
20. Zhao, F.; Malayev, V.; Rao, V.; Hussain, M. Effect of sodium lauryl sulphate in dissolution media on dissolution of hard gelatine capsule cells. Pharm. Res., 2004, 21, 144-148.
21. Kalantzi, L.; Goumas, K.; Kalioras, V.; Abrahamsson, B.; Dressman, J.B.; Reppas, C. Characterization of the human upper gastrointestinal contents under conditions simulating bio- availability/bioequivalence studies. Pharm. Res., 2006, 23, 165-176.
22. Macheras, P.; Koupparis, M.; Tsaprounis, C. Drug dissolution studies in milk using the automated flow injection serial dynamic dialysis technique. Int. J. Pharm., 1986, 33, 125-136.
23. Macheras, P.; Koupparis, M.; Apostolelli, E. Dissolution of 4 controlled-release theophylline formulations in milk. Int. J. Pharm., 1987, 36, 73-79.
24. Macheras, P.E.; Koupparis, M.A.; Antimisiaris, S.G. Effect of temperature and fat content on the binding of hydrochlorothiazide and chlorothiazide to milk. J. Pharm. Sci., 1988, 77, 334-336.
25. Macheras, P.; Koupparis, M.; Antimisiaris, S. An in vitro model for exploring CR theophylline-milk fat interactions. Int. J. Pharm., 1989, 54, 123-130.
26. Macheras, P.E.; Koupparis, M.A.; Antimisiaris, S.G. Effect of temperature and fat content on the solubility of hydrochlorothiazide and chlorothiazide in milk. J. Pharm. Sci., 1989, 78, 933-936.
27. Macheras, P.E.; Koupparis, M.A.; Antimisiaris, S.G. Drug binding and solubility in milk. Pharm. Res., 1990, 7, 537-541.
28. Buckton, G.; Beezer, A.E.; Chatham, S.M.; Patel, K.K. In vitro dissolution testing of oral controlled release preparations in the presence of artificial foodstuffs. 2. Probing drug food interactions using microcalorimetry. Int. J. Pharm., 1989, 56, 151-157.
29. Nicolaides, E.; Galia, E.; Efthymiopoulos, C.; Dressman, J.B.; Reppas, C. Forecasting the in vivo performance of four low solubility drugs from their in vitro dissolution data. Pharm. Res., 1999, 16, 1876-1882.
30. Ashby, L.J.; Beezer, A.E.; Buckton, G. In vitro dissolution testing of oral controlled release preparations in the presence of artificial foodstuffs. 1. Exploration of alternative methodology - Microcalorimetry. Int. J. Pharm., 1989, 51, 245-251.
31. Junginger, H.E.; Verhoeven, J.; Peschier, L.J.C. A new in vitro model to detect interactions between controlled release dosage forms and food. Acta Pharm. Technol., 1990, 36, 155-160.
32. Klein, S.; Butler, J.; Hempenstall, J.M.; Reppas, C.; Dressman, J.B. Media to simulate the postprandial stomach I. Matching the physicochemical characteristics of standard breakfasts. J. Pharm. Pharmacol., 2004, 56, 605-610.
33. Dressman, J.B.; Berardi, R.R.; Dermentzoglou, L.C.; Russel, T.L.; Schmalz, S.P.; Barnett, J.L.; Jarvenpaa, K.M. Upper gastrointestinal (GI) pH in young, healthy men and women. Pharm. Res., 1990, 7, 756-761.
34. Fotaki, N.; Symillides, M.; Reppas, C. Canine versus in vitro data for predicting input profiles of L-sulpiride after oral administration. Eur. J. Pharm. Sci., 2005, 26, 324-333.
35. Walstra, P.; Jennes, R.; Badings, H.T. Dairy Chemistry and Physics, John Wiley and sons, New York. 1984; pp. 89-270
36. Armand, M.; Borel, P.; Dubois, C.; Senft, M.; Peyrot, J.; Salducci, J.; Lafont, H.; Lairon, D. Characterization of emulsions and lipolysis of dietary lipids in the human stomach. Am. J. Physiol., 1994, 266, G372-G381.
37. McNamara, D.P.; Whitney, K.M.; Goss, S.L. Use of a physiologic bicarbonate buffer system for dissolution characterization of ionizable drugs. Pharm. Res., 2003, 20, 1641-1646.
38. Vertzoni, M.; Fotaki, N.; Kostewicz, E.; Stippler, E.; Leuner, C.; Nicolaides, E.; Dressman, J.; Reppas. C. Dissolution media simulating the intralumenal composition of the small intestine: physiological issues and practical aspects. J. Pharm. Pharmacol., 2004, 56, 453-462.
39. Pedersen, B.L.; Müllertz, A.; Brøndsted, H.; Kristensen, H.G. A comparison of the solubility of danazol in human and simulated gastrointestinal fluids. Pharm. Res., 2000, 17, 891-894.
40. Porter, C.; Charman, W. In vitro assessment of oral lipid based formulations. Adv. Drug Deliv. Rev., 2001, 50, S127-S147.
41. Zangenberg, N.H.; Müllertz, A.; Kristensen, H.G.; Hovgaard, L. A dynamic in vitro lipolysis model. I. Controlling the rate of lipolysis by continuous addition of calcium. Eur. J. Pharm. Sci., 2001, 14, 115-22.
42. Fatouros, D.G.; Mullertz, A. In vitro lipid digestion models in design of drug delivery systems for enhancing oral bioavailability. Expert Opin. Drug. Metab. Toxicol., 2008, 4, 65-76.
43. Fotaki, N.; Symillides, M.; Reppas, C. In vitro versus canine data for predicting input profiles of isosorbide-5-mononitrate from oral extended release products on a confidence interval basis. Eur. J. Pharm. Sci., 2005, 24, 115-122.
44. Diakidou, A.; Vertzoni, M.; Goumas, K.; Söderlind, E.; Abrahamsson, B.; Dressman, J.; Reppas, C. Characterization of the contents of ascending colon to which drugs are exposed after oral administration to healthy adults. Pharm. Res., 2009, 26, 2141-2151.
45. Sunesen, V.H.; Pedersen, B.L.; Kristensen, H.G.; Müllertz, A. In vivo in vitro correlations for a poorly soluble drug, danazol, using the flow-through dissolution method with biorelevant dissolution media. Eur. J. Pharm. Sci., 2005, 24, 305-313.
46. Abrahamsson, B.; Pal, A.; Sjoberg, M.; Carlsson, M.; Laurell, E.; Brasseur, J.G. A novel in vitro and numerical analysis of shear- induced drug release from extended-release tablets in the fed stomach. Pharm. Res., 2005, 22, 1215-1226.
47. Cammarn, S.R.; Sakr, A. Predicting dissolution via hydrodynamics: salicylic acid tablets in flow through cell dissolution. Int. J. Pharm., 2000, 201, 199-209.
48. Diebold, S.M. Physiological parameters relevant to dissolution testing: hydrodynamic considerations. In Pharmaceutical Dissolution Testing; Dressman, J., Krämer, J., Eds.; Taylor & Francis: London, UK, 2005; pp. 127-191.
49. Kukura, J.; Baxter, J.L.; Muzzio, F.J. Shear distribution and variability in the USP Apparatus 2 under turbulent conditions. Int. J. Pharm., 2004, 279, 9-17.
50. Filleborn, V.M. A new approach to tablet disintegration testing. Am. J. Pharm. Sci. Support Public Health, 1948, 120, 233-255.
51. Minekus, M.; Smeets-Peeters, M.; Bernalier, A.; Marol-Bonnin, S.; Havenaar, R.; Marteau, P.; Alric, M.; Fonty, G.; Huisin't Veld, J.H. A computer-controlled system to simulate conditions of the large intestine with peristaltic mixing, water absorption and absorption of fermentation products. Appl. Microbiol. Biotechnol., 1999, 53, 108-114.
52. Blanquet, S.; Zeijdner, E.; Beyssac, E.; Meunier, J.P.; Denis, S.; Havenaar, R.; Alric, M. A dynamic artificial gastrointestinal system for studying the behavior of orally administered drug dosage forms under various physiological conditions. Pharm. Res., 2004, 21, 585-591.
53. Indireshkumar, K.; Brasseur, J.G.; Faas, H.; Hebbard, G.S.; Kunz, P.; Dent, J.; Feinle, C.; Li, M.; Boesiger, P.; Fried, M.; Schwizer, W. Relative contributions of pressure pump and peristaltic pump to gastric emptying. Am. J. Physiol. Gastrointest. Liver Physiol., 2000, 278, G604-616.
54. Pallotta, N.; Cicala, M.; Frandina, C.; Corazziari, E. Antro-pyloric contractile patterns and transpyloric flow after meal ingestion in humans. Am. J. Gastroenterol., 1998, 93, 2513-2522.
55. Cassilly, D.; Kantor, S.; Knight, L.C.; Maurer, A.H.; Fisher, R.S.; Semler, J.; Parkman, H.P. Gastric emptying of a non-digestible solid: assessment with simultaneous SmartPill pH and pressure capsule, antroduodenal manometry, gastric emptying scintigraphy. Neurogastroenterol. Motil., 2008, 20, 311-319.
56. Schiller, C.; Frohlich, C.P.; Giessmann, T.; Siegmund, W.; Monnikes, H.; Hosten, N.; Weitschies, W. Intestinal fluid volumes and transit of dosage forms as assessed by magnetic resonance imaging. Aliment. Pharmacol. Ther., 2005, 22, 971-979.
57. th ed. W.B. Saunders Company: Philadelphia, USA, 1993; p. 486.
58. Abrahamsson, B.; Roos, K.; Sjogren, J. Investigation of prandial effects on hydrophilic matrix tablets. Drug Dev. Ind. Pharm., 1999, 25, 765-771.
59. Burke, M.; Maheshwari, C.R.; Zimmerman, B.O. Pharmaceutical analysis apparatus and method. USA Pat. WO 2006/0527420A2.
60. Garbacz, G.; Wedemeyer, R.S.; Nagel, S.; Giessmann, T.; Monnikes, H.; Wilson, C.G.; Siegmund, W.; Weitschies, W. Irregular absorption profiles observed from diclofenac extended release tablets can be predicted using a dissolution test apparatus that mimics in vivo physical stresses. Eur. J. Pharm. Biopharm., 2008, 70, 421-428.
61. Garbacz, G.; Golke, B.; Wedemeyer, R.S.; Axell, M.; Söderlind, E.; Abrahamsson, B.; Weitschies, W. Comparison of dissolution profiles obtained from nifedipine extended release once a day products using different dissolution test apparatuses. Eur. J. Pharm. Sci., 2009, 38, 147-155.
62. Kostewicz, E.S.; Brauns, U.; Becker, R.; Dressman J.B. Forecasting the oral absorption behavior of poorly soluble weak bases using solubility and dissolution studies in biorelevant media. Pharm, Res., 2002, 19, 345-349.
63. Defang, O.; Shufang, N.; Wei, L.; Hong, G.; Hui, L.; Weisan, P. In vitro and in vivo evaluation of two extended release preparations of combination metformin and glipizide. Drug Dev. Ind. Pharm., 2005, 31, 677-685.
64. Fotaki, N. In Vitro Release Data and In Vivo Canine Data for the Prediction of the Gastrointestinal Absorption of Drugs PhD Thesis, National and Kapodistrian University of Athens Greece, 2005.
65. Fotaki, N.; Aivaliotis, A.; Butler, J.; Dressman, J.; Fischbach, M.; Hempenstall, J.; Klein, S.; Reppas, C. A comparative study of different release apparatus in generating in vitro-in vivo correlations for extended release formulations. Eur. J. Pharm. Biopharm., 2009, 73, 115-120.
66. Jantratid, E.; De Maio, V.; Ronda, E.; Mattavelli, V.; Vertzoni, M.; Dressman, J.B. Application of biorelevant dissolution tests to the prediction of in vivo performance of diclofenac sodium from an oral modified-release pellet dosage form. Eur. J. Pharm. Sci., 2009, 37, 434-441.
67. Jantratid, E.; Janssen, N.; Chokshi, H.; Tang, K.; Dressman, J.B. Designing biorelevant dissolution tests for lipid formulations: case example--lipid suspension of RZ-50. Eur. J. Pharm. Biopharm., 2008, 69, 776-785.
68. Okumu, A.; DiMaso, M.; Löbenberg, R. Dynamic dissolution testing to establish in vitro/in vivo correlations for montelukast sodium, a poorly soluble drug. Pharm. Res., 2008, 25, 2778-2785.
69. Lue, B.M.; Nielsen, F.S.; Magnussen, T.; Schou, H.M.; Kristensen, K.; Jacobsen, L.O.; Müllertz, A. Using biorelevant dissolution to obtain IVIVC of solid dosage forms containing a poorly-soluble model compound. Eur. J. Pharm. Biopharm., 2008, 69, 648-657.